<?xml version="1.0" encoding="UTF-8"?>
<p>Danoprevir was approved in China as an HCV NS3 protease inhibitor. It may be used to treat non-cirrhotic genotype 1b chronic hepatitis C, combined with ribavirin, ritonavir and peginterferon-Î± [
 <xref rid="B75-medicina-56-00386" ref-type="bibr">75</xref>]. Currently, a trial study has been initiated for its use against COVID-19.
</p>
